Research graph
References from Significance of next-generation sequencing in the era of targeted therapy for biliary tract cancer: an analysis at a single institution. Local targets link to admitted publications; unresolved targets remain external evidence.
Current insights and future perspectives of treatment strategies for biliary tract cancer
10.4251/wjgo.v17.i10.110415 · 2025 · External reference
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
10.1056/nejmoa0908721 · 2010 · External reference
Randomized phase III study of gemcitabine, cisplatin plus S-1 versus gemcitabine, cisplatin for advanced biliary tract cancer (KHBO1401 - MITSUBA)
10.1002/jhbp.1219 · 2023 · External reference
Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer
10.1056/evidoa2200015 · 2022 · External reference
Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial
10.1016/s0140-6736(23)00727-4 · 2023 · External reference
Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial
10.1016/s1470-2045(21)00027-9 · 2021 · External reference
SWOG S1815: A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers
10.1200/jco-24-01383 · 2025 · External reference
Adjuvant S-1 compared with observation in resected biliary tract cancer (JCOG1202, ASCOT): a multicentre, open-label, randomised, controlled, phase 3 trial
10.1016/s0140-6736(22)02038-4 · 2023 · External reference
C-CAT: The National Datacenter for Cancer Genomic Medicine in Japan
10.1158/2159-8290.cd-22-0417 · 2022 · External reference
Genomic spectra of biliary tract cancer
10.1038/ng.3375 · 2015 · External reference
Building a staircase to precision medicine for biliary tract cancer
10.1038/ng.3386 · 2015 · External reference
Trends in oncology drug lags in Japan from 2001 to 2020: A cross-sectional study
10.1111/cts.13660 · 2023 · External reference
A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)
10.1093/annonc/mdy263 · 2018 · External reference
The impact of targeted therapies on molecular alterations identified by an institutional molecular tumor board: an approach based on ESCAT classification
10.1016/j.esmorw.2024.100092 · 2024 · External reference
Precision Medicine Targeting FGFR2 Genomic Alterations in Advanced Cholangiocarcinoma: Current State and Future Perspectives
10.3389/fonc.2022.860453 · 2022 · External reference
Molecular profiling of biliary tract cancer: a target rich disease
10.21037/jgo.2016.09.01 · 2016 · External reference
Molecular detection and clinicopathological characteristics of advanced/recurrent biliary tract carcinomas harboring the FGFR2 rearrangements: a prospective observational study (PRELUDE Study)
10.1007/s00535-020-01735-2 · 2021 · External reference
Prognostic value of FGFR2 alterations in patients with iCCA undergoing surgery or systemic treatments: A meta-analysis
10.1111/liv.15984 · 2024 · External reference
Frequency and prognostic significance of isocitrate dehydrogenase 1 mutations in cholangiocarcinoma: a systematic literature review
10.21037/jgo.2019.03.10 · 2019 · External reference
Epidemiology, pathogenesis, biology and evolving management of MSI-H/dMMR cancers
10.1038/s41571-025-01015-z · 2025 · External reference
Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial
10.1016/s1470-2045(20)30321-1 · 2020 · External reference
Molecular insights into HER2/ERBB2 amplification and carcinogenesis in gallbladder cancer associated with pancreaticobiliary maljunction
10.1007/s00535-025-02303-2 · 2025 · External reference
Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study
10.1016/s1470-2045(23)00242-5 · 2023 · External reference
Expansion of Cancer Risk Profile for
10.1001/jamaoncol.2022.0476 · 2022 · External reference
ESMO Scale for Clinical Actionability of Molecular Targets Driving Targeted Treatment in Patients with Cholangiocarcinoma
10.1158/1078-0432.ccr-21-2384 · 2022 · External reference
Pre-Analytical Considerations for Successful Next-Generation Sequencing (NGS): Challenges and Opportunities for Formalin-Fixed and Paraffin-Embedded Tumor Tissue (FFPE) Samples
10.3390/ijms17091579 · 2016 · External reference
Liquid biopsy in cancer: current status, challenges and future prospects
10.1038/s41392-024-02021-w · 2024 · External reference
Expansion of Cancer Risk Profile for
10.1001/jamaoncol.2022.0476 · ExternalCitation · doi-reference
Randomized phase III study of gemcitabine, cisplatin plus S-1 versus gemcitabine, cisplatin for advanced biliary tract cancer (KHBO1401 - MITSUBA)
10.1002/jhbp.1219 · ExternalCitation · doi-reference
Molecular detection and clinicopathological characteristics of advanced/recurrent biliary tract carcinomas harboring the FGFR2 rearrangements: a prospective observational study (PRELUDE Study)
10.1007/s00535-020-01735-2 · ExternalCitation · doi-reference
Molecular insights into HER2/ERBB2 amplification and carcinogenesis in gallbladder cancer associated with pancreaticobiliary maljunction
10.1007/s00535-025-02303-2 · ExternalCitation · doi-reference
The impact of targeted therapies on molecular alterations identified by an institutional molecular tumor board: an approach based on ESCAT classification
10.1016/j.esmorw.2024.100092 · ExternalCitation · doi-reference
Adjuvant S-1 compared with observation in resected biliary tract cancer (JCOG1202, ASCOT): a multicentre, open-label, randomised, controlled, phase 3 trial
10.1016/s0140-6736(22)02038-4 · ExternalCitation · doi-reference
Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial
10.1016/s0140-6736(23)00727-4 · ExternalCitation · doi-reference
Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial
10.1016/s1470-2045(20)30321-1 · ExternalCitation · doi-reference
Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial
10.1016/s1470-2045(21)00027-9 · ExternalCitation · doi-reference
Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study
10.1016/s1470-2045(23)00242-5 · ExternalCitation · doi-reference
Genomic spectra of biliary tract cancer
10.1038/ng.3375 · ExternalCitation · doi-reference
Building a staircase to precision medicine for biliary tract cancer
10.1038/ng.3386 · ExternalCitation · doi-reference
Liquid biopsy in cancer: current status, challenges and future prospects
10.1038/s41392-024-02021-w · ExternalCitation · doi-reference
Epidemiology, pathogenesis, biology and evolving management of MSI-H/dMMR cancers
10.1038/s41571-025-01015-z · ExternalCitation · doi-reference
Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer
10.1056/evidoa2200015 · ExternalCitation · doi-reference
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
10.1056/nejmoa0908721 · ExternalCitation · doi-reference
A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)
10.1093/annonc/mdy263 · ExternalCitation · doi-reference
Trends in oncology drug lags in Japan from 2001 to 2020: A cross-sectional study
10.1111/cts.13660 · ExternalCitation · doi-reference
Prognostic value of FGFR2 alterations in patients with iCCA undergoing surgery or systemic treatments: A meta-analysis
10.1111/liv.15984 · ExternalCitation · doi-reference
ESMO Scale for Clinical Actionability of Molecular Targets Driving Targeted Treatment in Patients with Cholangiocarcinoma
10.1158/1078-0432.ccr-21-2384 · ExternalCitation · doi-reference
C-CAT: The National Datacenter for Cancer Genomic Medicine in Japan
10.1158/2159-8290.cd-22-0417 · ExternalCitation · doi-reference
SWOG S1815: A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers
10.1200/jco-24-01383 · ExternalCitation · doi-reference
Molecular profiling of biliary tract cancer: a target rich disease
10.21037/jgo.2016.09.01 · ExternalCitation · doi-reference
Frequency and prognostic significance of isocitrate dehydrogenase 1 mutations in cholangiocarcinoma: a systematic literature review
10.21037/jgo.2019.03.10 · ExternalCitation · doi-reference
Precision Medicine Targeting FGFR2 Genomic Alterations in Advanced Cholangiocarcinoma: Current State and Future Perspectives
10.3389/fonc.2022.860453 · ExternalCitation · doi-reference
Pre-Analytical Considerations for Successful Next-Generation Sequencing (NGS): Challenges and Opportunities for Formalin-Fixed and Paraffin-Embedded Tumor Tissue (FFPE) Samples
10.3390/ijms17091579 · ExternalCitation · doi-reference
Current insights and future perspectives of treatment strategies for biliary tract cancer
10.4251/wjgo.v17.i10.110415 · ExternalCitation · doi-reference
